Market evolution: Toxins and cultures (CN 300249) — 2015–2025

Introduction

This report analyses the EU's external trade in products classified under customs code CN 300249 — Toxins, cultures of micro-organisms and similar products (excl. yeasts and vaccines). This residual heading within CN 30 covers a diverse range of biological products used in diagnostics, research, and industrial applications. Although the analysis window spans 2015–2025, complete annual data are available only from 2022 through 2025. All comparisons in this report therefore rely on that four-year period.

Over these four years, the EU consolidated its position as a dominant net exporter of toxins and microbial cultures, yet the market underwent several striking structural shifts: export volumes doubled while unit prices fell sharply; import values surged even faster, driven by rising unit costs and growing demand from the United States and the United Kingdom; and the internal geography of EU trade shifted meaningfully, with previously dominant exporters losing ground to fast-growing newcomers. The report examines these dynamics in three sections.

1. A Booming Volume Market Eroding on Price

The most striking feature of the 2022–2025 period is the sharp divergence between quantity growth and price evolution on both the export and import sides.

Export quantities doubled while prices fell by over 40 %

EU exports to non-EU countries grew from a value of €5.82 billion in 2022 to €6.86 billion in 2025, an increase of 17.7 %. Behind that moderate headline figure, however, lies a far more dramatic volume story: export quantities surged from 14,476 tonnes to 29,263 tonnes (+102.2 %). The corresponding unit price dropped from €402,278 per tonne to €233,753 per tonne (–41.9 %), indicating that the EU's export growth was volume-driven rather than price-driven.

This pattern is consistent with a maturing competitive landscape in which European producers—particularly in Ireland, Germany, and the Netherlands—are expanding output aggressively, potentially at the cost of pricing power. It may also reflect a compositional shift toward higher-volume, lower-value-added products within the CN 300249 basket.

Import values more than tripled, driven by both volume and price

On the import side, the picture is almost the mirror image in price terms. EU imports rose from €397.7 million to €1.46 billion (+267.6 %), far outpacing the quantity increase of 50.7 % (from 3,594 t to 5,417 t). Import unit prices more than doubled, rising from €108,478/t to €268,162/t (+147.2 %). Unlike exports, the EU's import growth was therefore driven by both volume expansion and significantly higher unit costs.

The import price increase likely reflects a rising share of higher-value specialised biological inputs sourced from the US and the UK, as well as possible supply-side constraints or inflationary pressures in those markets.

The EU's trade surplus remained massive but flat

Despite the surge in imports, the EU remained a dominant net exporter. The trade balance moved from €5.43 billion in 2022 to €5.39 billion in 2025 (–0.6 %). The net import reliance remained deeply negative at approximately –206 %, confirming that the EU exports roughly three times more value in CN 300249 products than it imports.

2. Geographical Concentration and New Partner Dynamics

Trade in CN 300249 is heavily concentrated geographically, though concentration trends diverge between imports and exports. The United States dominates both sides of the equation, while other partners have seen remarkable shifts.

The US remained the EU's largest trade partner on both sides

On the export side, the United States absorbed €4.15 billion of EU exports in 2025, up 13.1 % from €3.67 billion in 2022. It remained overwhelmingly the single largest destination, accounting for roughly 60 % of EU CN 300249 exports by value. Brazil (+28.2 %), the United Kingdom (+21.9 %), and Russia (+317.6 %) were the next largest destinations.

On the import side, the United States supplied €889 million of EU imports in 2025 (+232.4 % from €267 million), representing over 60 % of total imports. The United Kingdom emerged as a fast-growing supplier, with imports surging from €32 million to €317 million (+888.2 %)—the fastest growth rate among all top partners. Switzerland (+412.5 %) and Ukraine (+312.2 %) also grew rapidly from smaller bases.

The UK's post-Brexit emergence is a defining feature

The most notable geographical story is the United Kingdom's explosive growth as both an import source (+888 %) and an export destination (+22 %). Prior to Brexit, much of this trade was internal to the EU and would not have appeared in extra-EU statistics. The magnitude of the UK's import growth into the EU—particularly if weighted by its small starting base—strongly suggests that supply chains which were previously invisible (being intra-EU) now register as cross-border trade. The UK has become the EU's second-largest import source for CN 300249 products, behind only the United States.

Russia's export surge warrants attention

EU exports to Russia grew by 317.6 %, from €106 million to €442 million, making Russia the EU's second-largest single-country export destination by value. This increase occurred despite the geopolitical context of 2022–2025. The category CN 300249 likely includes biological products that may fall outside the scope of sanctioned goods, which could explain the continued growth. However, given the residual nature of this heading and the high volatility of Russia-linked trade flows (coefficient of variation of 0.60 for imports, 0.22 for exports), this relationship merits close monitoring.

Import concentration decreased modestly

The Herfindahl-Hirschman Index (HHI) for import concentration by value fell from 4,793 to 4,254 (–11.2 %), and for volume from 2,629 to 2,236 (–14.9 %). While these values still indicate a highly concentrated import market (an HHI above 2,500 is typically considered highly concentrated), the decline points to gradual diversification—driven largely by the rise of the UK and Switzerland as alternative suppliers to the US. Export concentration also eased slightly, with the value-based HHI falling from 4,113 to 3,838 (–6.7 %).

3. Intra-EU Specialisation and the Rise of New Export Hubs

The internal structure of the EU's CN 300249 trade is characterised by extreme specialisation in a handful of Member States, but the balance of power is shifting.

Ireland remained the dominant exporter but lost ground

Ireland was by far the largest EU exporter, shipping €4.10 billion in 2025. However, this represented a decline of 11.1 % from the €4.61 billion recorded in 2022, and its share of total EU exports fell accordingly. Ireland's Revealed Symmetric Comparative Advantage (RSCA) of 0.86 and RCA of 13.24 mark it as extraordinarily specialised in this product category—consistent with the presence of major biopharmaceutical manufacturing clusters in Ireland.

Germany and the Netherlands emerged as fast-growing exporters

The most dramatic intra-EU shifts occurred in Germany (exports +156.6 %, from €307 million to €788 million) and the Netherlands (exports +1,085.8 %, from €53 million to €626 million). The Netherlands' more-than-tenfold increase is remarkable and may reflect the country's role as a logistics and re-export hub, or the scaling up of domestic biotech production. Italy (+144.6 %) also showed strong growth from a smaller base.

Import patterns within the EU also shifted significantly

On the import side, France saw the most dramatic increase (+1,358.3 %, from €20 million to €296 million), followed by Germany (+508.8 %, from €39 million to €235 million) and Ireland (+309.5 %, from €38 million to €155 million). Belgium and the Netherlands also showed substantial growth.

The simultaneous growth of both imports and exports in countries like Germany, Ireland, and the Netherlands is characteristic of processing and re-export trade, where Member States import raw or semi-processed biological materials for further refinement and subsequent export. This is consistent with the known structure of the EU's biopharmaceutical value chain.

Austria and Denmark showed strong specialisation

After Ireland, Austria (RSCA = 0.59, RCA = 3.82) and Denmark (RSCA = 0.57, RCA = 3.67) were the most specialised EU Member States in CN 300249 products, indicating that these products represent a significantly larger share of their exports than the EU average. By contrast, several Member States—including Cyprus, Romania, Croatia, and Portugal—showed near-zero specialisation (RSCA below –0.95), confirming that the EU's CN 300249 production is geographically concentrated in a handful of northern and western European economies.

Conclusion

The EU's trade in toxins, cultures of micro-organisms, and similar products (CN 300249) experienced a period of rapid growth between 2022 and 2025, characterised by three dominant trends: a volume-driven export expansion that came at the cost of lower unit prices; a surging import bill fuelled by rising demand and higher-value sourcing from the US and the UK; and a geographical reshuffling both externally (the UK's post-Brexit emergence as a major partner, Russia's unexpected growth as an export destination) and internally (the Netherlands and Germany challenging Ireland's dominance as the EU's primary exporter).

The EU's structural position as a massive net exporter in this product category—with a trade surplus exceeding €5 billion and a net import reliance of approximately –206 %—remained firmly intact. However, the simultaneous rise in imports and the erosion of export prices suggest that competitive pressures and evolving supply-chain configurations are reshaping the market. The continued concentration of trade flows (HHI still above 3,800 on the export side and 4,200 on the import side) implies that disruptions to key partners—particularly the United States—could have outsized effects. Going forward, the ability of second-tier EU exporters such as the Netherlands, Germany, and Italy to sustain their rapid growth will be a critical factor in determining whether the EU's trade surplus in this vital biotechnology segment remains resilient.